Top Story Today
J&J's $16.6 Billion Heart Pump Just Lost Two High-Profile Trials
The Impella heart pump failed to meet primary endpoints in two major trials presented at the American College of Cardiology meeting. In the CHIP-BCIS3 study, cardiovascular death nearly doubled in patients who received the pump (26.7% vs. 14.5%). The STEMI-DTU trial showed zero benefit in heart attack patients while adding 47 minutes of delay before opening blocked arteries. Both trials tested the exact procedures where Impella is used most often, putting J&J's $16.6 billion Abiomed acquisition under a harsh spotlight.
Why it matters: These results expose a pattern that haunts medical devices broadly: widespread adoption driven by physician enthusiasm and registry data, long before randomized trials prove the technology actually works. Outside of cardiogenic shock, the evidence case for the world's most popular heart pump just got dramatically weaker.
Read more →Deals and Strategy
Merck Bets $6.7 Billion on a Cancer Drug in Phase 1/2
Merck is paying $6.7 billion (a 42% premium) for Terns Pharmaceuticals and its leukemia drug TERN-701, currently in a Phase 1/2 trial. The deal screams urgency: Keytruda, which generates nearly $30 billion annually, starts losing patent protection in 2028. Terns pivoted from liver disease to oncology last year, turning a small-cap stock into a blockbuster acquisition target. Pivotal trial data isn't expected until late 2026 at the earliest.
Read more →Blackstone Closes the Largest Life Sciences Fund Ever at $6.3B
Blackstone's oversubscribed BXLS VI fund hit its hard cap, nearly 40% larger than its predecessor. The firm's life sciences platform now manages $15 billion, boasts an 86% Phase 3 success rate (industry average hovers around 50-60%), and has notched 34 regulatory approvals. The record raise signals that institutional investors aren't fleeing biotech; they're just getting pickier about who manages the money.
Read more →Takeda Cuts 634 More U.S. Jobs, Bringing Two-Year Total to 2,500
Another round of layoffs at Takeda, with 247 roles in Massachusetts and 387 elsewhere. The company is spending nearly $1 billion on restructuring to save $1.3 billion annually by FY2028, banking on six late-stage pipeline assets to generate $10 to $20 billion in collective peak sales. New CEO Julie Kim inherits the transformation in June.
Read more →Clinical and Regulatory
Merck's Cholesterol Pill Could Make PCSK9 Injections Obsolete
Merck's oral PCSK9 inhibitor enlicitide cut LDL cholesterol by nearly 60% in Phase 3 trials, matching injectable rivals like Repatha and Praluent. The real killer stat: ≥97% adherence, compared to the dismal rates seen with biweekly injections that patients keep quitting. The cardiovascular outcomes trial (14,500 patients enrolled) will determine whether this becomes the default cholesterol drug for millions.
Read more →FDA Approves First Drug Designed to Cross the Blood-Brain Barrier
Denali Therapeutics' Avlayah won accelerated approval for Hunter syndrome, becoming the first biologic engineered to penetrate the blood-brain barrier. Patients showed a 91% reduction in toxic brain sugar buildup. For 20 years, the only available treatment helped kids' bodies but couldn't reach their brains. The underlying Transport Vehicle platform could open doors for Alzheimer's and other neurological diseases.
Read more →Astellas Kills STING Inhibitor Trial Before Generating Human Data
Astellas pulled the plug on ASP5502 for Sjogren's syndrome, citing strategic priorities. The decision adds to a growing graveyard of STING pathway programs that have struggled with poor bioavailability and selectivity challenges. The silver lining for Sjogren's patients: Novartis' ianalumab earned Breakthrough Therapy designation in January and could become the disease's first targeted therapy ever.
Read more →IPOs and Pivots
The Billion-Dollar Obesity Startup Wants to Go Public
Kailera Therapeutics filed for a Nasdaq IPO after raising nearly $1 billion in private funding over two years. Its lead drug ribupatide delivered 22.8% weight loss in Phase 2, and the company plans a head-to-head trial against Wegovy. CEO Ron Renaud previously built Cerevel (sold to AbbVie for $8.7 billion), so he knows the playbook. Phase 3 data arrives in 2028.
Read more →Bicycle Therapeutics Lays Off 30% After Padcev Proves Unbeatable
Bicycle shelved its bladder cancer drug zelenectide after the FDA determined the existing trial design was no longer acceptable as an approval path, and a head-to-head trial against Pfizer's Padcev was something the small biotech couldn't afford. Padcev hits a 68% response rate. The company is pivoting to pancreatic cancer and radioconjugates, with $628 million in cash stretching its runway to 2030.
Read more →